Closed-Loop Insulin Pumps Show Real Benefits During Pregnancy With Type 1 Diabetes

Managing blood sugar during pregnancy with Type 1 diabetes is demanding work. High blood sugar raises the risk of pregnancy complications—studies suggest hyperglycemia-related problems occur in roughly half of all pregnant women with Type 1 diabetes. Standard care, even with continuous glucose monitors, often falls short of pregnancy targets.

A new randomized clinical trial called CIRCUIT tested whether closed-loop insulin systems could improve these outcomes. The trial enrolled 91 pregnant women at 14 clinical centers in Canada and Australia, randomizing them to either a closed-loop system or standard care (insulin pump or injections) combined with continuous glucose monitoring. Researchers measured how much time participants spent in the pregnancy-specific glucose target range of 63–140 mg/dL between 16 and 34 weeks of pregnancy.

The results were clear: women using closed-loop systems spent a mean of 65.4% of the time in target range, compared to 50.3% for the standard care group—a difference of about 12.5 percentage points. This is meaningful because even small improvements in time spent in target range during pregnancy can reduce the risk of complications.

Closed-loop insulin delivery, often called 'artificial pancreas' technology, automates part of insulin dosing. The system reads glucose values from a continuous glucose monitor and automatically adjusts insulin delivery from a pump without requiring the user to manually calculate and enter each dose.

This automation is particularly valuable during pregnancy, when blood sugar targets are tighter and hormonal changes make glucose patterns unpredictable. Instead of constant manual fine-tuning, the algorithm does much of the work, reducing the cognitive and physical burden of diabetes management during an already complex time.

Safety is always a primary concern when evaluating new diabetes technology. In the CIRCUIT trial, severe hypoglycemia (dangerously low blood sugar) was rare in both groups—just one episode in the closed-loop group. Diabetic ketoacidosis, a serious metabolic emergency, occurred twice in the closed-loop group and once in standard care. These rates were comparable between groups, suggesting the closed-loop system did not introduce new safety risks.

Beyond time in range, the closed-loop group showed additional improvements: reduced time spent high and increased time in range overnight, when many pregnant women struggle with glucose stability. These benefits matter for both mother and baby.

While CIRCUIT is important evidence, closed-loop systems are still not yet standard pregnancy care. The technology remains newer, access varies by region and insurance coverage, and implementation requires training and support from specialized diabetes and obstetric teams.

However, the evidence is accumulating. Continuous glucose monitoring during pregnancy has already been shown to reduce complications in Type 1 diabetes, and now closed-loop delivery adds another layer of automation. If you are pregnant or planning pregnancy with Type 1 diabetes, discussing whether a closed-loop system might be right for you is worth having with your diabetes care team. These systems are not a cure and do not replace careful glucose monitoring and clinical oversight—but for some people, they can meaningfully ease the management burden and improve blood sugar control during this critical nine months.

Origin: YouTube / Diabetech (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.